All In Biotech

NDA 019998 · Recordati Rare

Chemet

Succimer · Oral · Lead Chelator

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Sep 16, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1991

Jan 30, 1991

Approved uses

1

Original approval plus efficacy supplements

Registered trials

7

1 Phase 3, 2 recruiting

FAERS reports

71

35 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 10, 2025.

CHEMET is indicated for the treatment of lead poisoning in pediatric patients aged 1 year and older with blood lead levels above 45 mcg/dL. CHEMET is a lead chelator indicated for the treatment of lead poisoning in pediatric patients aged 1 year and older with blood lead levels above 45 mcg/dL. ( 1 ) Limitations of Use CHEMET is not indicated for prophylaxis of lead poisoning in a lead-containing environment. ( 1 ) CHEMET does not cross the blood-brain barrier and is not indicated to treat encephalopathy associated with lead toxicity. ( 1 ) Limitations of Use CHEMET is not indicated for prophylaxis of lead poisoning in a lead-containing environment. CHEMET does not cross the blood-brain barrier and is not indicated to treat encephalopathy associated with lead toxicity.

Mechanism: Succimer is a lead chelator; it forms water soluble chelates and, consequently, increases the urinary excretion of lead.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 30, 1991 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • CHEMET · SUCCIMER 100MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Succimer" as an intervention, any sponsor and status, largest first.

All 7 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use23
  • product availability issue9
  • arthralgia6
  • hypertension5
  • no adverse event5
  • weight increased5
  • condition aggravated4
  • dizziness4
  • skin striae4
  • abdominal pain upper3
  • arrhythmia3
  • asthenia3

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20094
20111
20123
20141
201615
20177
20183
20192
20201
20215
202216
20234
20242
20253
20264

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Chemet (Succimer)

2024 spending

$92K

Beneficiaries

27

44 claims

Per beneficiary

$3,393

$21.89 per unit

View as table
YearSpending
2020$286,690
2021$69,032
2022$272,862
2023$152,630
2024$91,613

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 19 on PubMed

Sponsor: Recordati Rare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.